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MaOBJECTIVES The aim of this study was to identify predictors of occlusion intolerance (OI) developing during proximal
protected carotid artery stenting (CAS).
BACKGROUND The use of proximal embolic protection devices, such as endovascular occlusion, during CAS has
been demonstrated to be particularly safe and effective. However, endovascular occlusion can expose the ipsilateral
hemisphere to hypoperfusion and produce transient neurological symptoms (OI).
METHODS From March 2010 to March 2012, 605 consecutive patients underwent proximal protected CAS at our
institution. To identify independent predictors of OI, a multivariate logistic regression model was developed that included
all patients’ clinical/angiographic and procedural characteristics.
RESULTS OI developed in a total of 184 patients (30.4%). Compared with patients in whom OI did not develop, those
who experienced OI had lower occlusion pressure (OP) (42.3  12.7 mm Hg vs. 61.9  15.4 mm Hg, p < 0.001). Receiver-
operating characteristic curve analysis demonstrated that OP was the most consistent predictor of OI with a C-statistic
of 0.85 (95% conﬁdence interval [CI]: 0.82 to 0.88) with best cutoff being #40 mm Hg (sensitivity, 68.5%; speci-
ﬁcity, 93.3%). By logistic regression analysis, the most powerful independent predictor of OI developing was an
OP #40 mm Hg (odds ratio: 33.2, 95% CI: 19.1 to 57.7) and the most powerful clinical predictor of such OP was the
presence of contralateral internal carotid artery occlusion (odds ratio: 3.1, 95% CI: 1.5 to 6.2).
CONCLUSIONS OI may occur in as many as one-third of the patients undergoing proximal protected CAS. This event
is more common in those patients with an OP #40 mm Hg. Patients presenting with concomitant occlusion of the
contralateral internal carotid artery more frequently have an OP #40 mm Hg. (J Am Coll Cardiol Intv 2014;7:1237–44)
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ACT = activated clotting time
CAS = carotid artery stenting
CCA = common carotid artery
CI = conﬁdence interval
ECA = external carotid artery
EPD = embolic protection
device
ICA = internal carotid artery
MACE = major adverse
cardiac event(s)
OI = occlusion intolerance
OP = occlusion pressure
OR = odds ratio
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1238with consequent transient neurological
symptoms (occlusion intolerance [OI]) (2,4).
The ability to predict in advance the risk of
OI, which is relatively frequent (3,4), might
help the operators to be ready to deal with
this event.
Thus, the aim of the present study was to
identify the predictors of developing carotid
OI during proximal protected CAS.
METHODS
STUDY POPULATION. From January 2010 to
March 2012, 605 consecutive patients un-
derwent CAS using endovascular occlusion
with a proximal EPD at our institution. In-clusion criteria were the degree of internal carotid
artery (ICA) stenosis, determined by angiography ac-
cording to the North American Symptomatic Carotid
Endarterectomy Trial Criteria (3): 1) asymptomatic
stenosis $80% and 2) symptomatic stenosis $50%.
Symptomatic was deﬁned a carotid stenosis occurring
within 6 months before the intervention, with
amaurosis fugax, ipsilateral hemispheric transient
ischemic attack, or ipsilateral ischemic stroke not
resulting in a major residual neurological deﬁcit
(stroke scales: Barthel score #60; National Institutes
of Health Stroke Scale score $15, or Rankin Scale
score >3).
Patients with the following criteria were excluded:
1) presence of a critical stenosis of the ipsilateral
CCA; occlusion of the ipsilateral external carotid ar-
tery (ECA); 3) contraindication to thienopyridines;
and 4) refused to provide informed consent before
enrollment.
CLINICAL ASSESSMENT. In each patient, clinical
history and risk factors were assessed. Smokers
included current and former smokers. Hypertension
was diagnosed if the systolic arterial pressure was
>140 mm Hg and/or diastolic arterial pressure was
>90 mm Hg on repeated measurements or if the
patient used antihypertensive drugs. Hypercholes-
terolemia was diagnosed if plasma total cholesterol
was >200 mg/dl, plasma low-density lipoprotein
cholesterol was >130 mg/dl, or if the patient used
lipid-lowering drugs because of a history of hyper-
cholesterolemia. Diabetes mellitus was diagnosed
if plasma fasting glucose was >126 mg/dl or if the
patient used hypoglycemic agents. Hospital records
documented previous cardiovascular events or other
comorbid conditions.
TECHNIQUE OF THE CAS PROCEDURE. All pro-
cedures were performed percutaneously with thepatient under local anesthesia. At the procedure
start, an 8- to 9-F, 25-cm long introducer sheath
(Terumo, Tokyo, Japan) was inserted in the infrarenal
aorta via the common femoral artery. After aortic
arch angiography, selective bilateral carotid artery
catheterization was performed using a 5-F JR4 diag-
nostic catheter advanced over a 0.035-inch soft
hydrophilic wire (Standard Glidewire, Terumo).
Once diagnostic angiography was completed, the
wire was advanced into 1 of the ECA distal branches,
the diagnostic catheter was advanced in the distal
ECA, and then the hydrophilic wire was exchanged
for a 300-cm, 0.035-inch stiff wire (Hi-Torque
Supracore, Abbott Vascular, Abbott Park, Illinois).
The endovascular occlusion device (Mo.Ma system,
Medtronic Inc., Santa Rosa, California) was guided
over the stiff wire until the radiopaque marker of
the distal balloon was located in the ECA, at w1 cm
beyond bifurcation and in proximity to or at the
superior thyroid artery (6). Then the distal balloon
was inﬂated in the ECA and the proximal balloon in
the CCA, thus blocking the antegrade and the
retrograde ﬂow across the target vessel. A 0.014-inch
wire was then navigated through the ICA stenosis.
Lesion pre-dilation was left to the operator’s
discretion, and self-expanding carotid stents were
deployed (Carotid Wallstent, Boston Scientiﬁc,
Natick, Massachusetts; X-Act, Abbott Vascular;
Precise, Cordis, Miami Lakes, Florida; Acculink,
Abbott Vascular; Cristallo Ideale, Medtronic). After
post-dilation, at least 60 ml of blood was aspirated
and ﬁltered through sieves, checking for visible
plaque debris. Blood ﬂow was restored only after 3
consecutive aspirations free of debris, deﬂating ﬁrst
the distal balloon and then the proximal balloon. The
ﬁnal angiography included ipsilateral biplane carotid
and intracranial views (3).
CONCOMITANT THERAPY. All patients received
aspirin (75 to 160 mg/day) and should have been on
ticlopidine (250 mg twice daily) for at least 7 days.
Alternatively, patients received clopidogrel preload
(300 mg) 24 h before the procedure. After the proce-
dure, thienopyridines were continued for at least
3 months, whereas aspirin was continued for life.
For anticoagulation, 70 to 100 IU/kg of heparin was
administered before wiring the ECA, with the inten-
tion to achieve an activated clotting time (ACT)
>250 s. Additional heparin was administered at the
operator’s discretion according to ACT values (7).
POST-PROCEDURAL PATIENT MANAGEMENT. Femoral
sheaths were removed when the ACT was <150 s.
Access site hemostasis was achieved by manual
compression in all patients. If clinical signs of limb
TABLE 1 Baseline Characteristics of the Study Population
(N ¼ 605)
Age, yrs 70.8  8.0
Age $80 yrs 88 (14.5)
Males 421 (69.6)
High surgical risk 289 (47.8)
Risk factors
Smoking 437 (72.2)
Hypertension 546 (90.2)
Hypercholesterolemia 482 (79.7)
Diabetes mellitus 204 (33.7)
Comorbidity
CAD 321 (53.1)
Symptomatic CVD 111 (18.3)
COPD 62 (10.2)
Medications
Antiplatelet agents 605 (100.0)
Beta-blockers 272 (45.0)
RAS inhibitors 448 (74.0)
Statins 428 (70.7)
Carotid features
Right ICA stenosis % 55.3 (37.4)
Left ICA stenosis % 53.2 (38.0)
ICA stenosis $90% 184 (30.4)
Ipsilateral ECA stenosis >75% 22 (3.6)
Contralateral ICA stenosis 75%–100% 91 (15.1)
Contralateral ICA stenosis 75%–99% 55 (9.1)
Contralateral occlusion 36 (6.0)
Values are mean  SD or n (%).
CAD ¼ coronary artery disease; CVD ¼ cerebrovascular disease; COPD ¼ chronic
obstructive pulmonary disease; ECA ¼ external carotid artery; ICA ¼ internal
carotid artery; RAS ¼ renin-angiotensin system.
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1239ischemia occurred on the side of femoral access,
sheaths were removed independently of post-
procedural time and ACT values. A complete blood
count was obtained before the CAS procedure and
before hospital discharge. An independent neurolo-
gist assessed all patients (3).
DEFINITIONS AND ENDPOINTS. OI was deﬁned as
any transient neurological deﬁcit observed during
occlusion time, but showing a complete recovery
within 20 min after restoring antegrade ﬂow (4).
Occlusion time (time of ﬂow blockage) was deﬁned
as the time from the inﬂation to the deﬂation of
the proximal balloon in the CCA (3).
Device success was deﬁned as the ability to posi-
tion, deploy, and retrieve the intact Mo.Ma device
during the index procedure (3). Protection success was
deﬁned as complete blockade of antegrade blood ﬂow
in the ICA throughout the entire procedure (3).
Technical success was deﬁned as device success and
the ability to successfully implant a carotid stent with
a residual ICA stenosis <30% (3). Procedural success
was deﬁned as technical success without the occur-
rence of any major adverse cardiac or cerebrovascular
event or unresolved OI during the index procedure.
The primary endpoint of the study was to eval-
uate the incidence of OI and the predictors of OI
development.
The secondary endpoint of the study was to eval-
uate the incidence of major adverse cardiovascular
events (MACE), including death, myocardial infarc-
tion, and any stroke in-hospital and at 30 days be-
tween patients in whom OI developed and those who
did not have this procedural complication.
Neurological complications were classiﬁed as one
of the following: 1) minor stroke deﬁned as a new
neurological deﬁcit that either resolves completely
within 30 days or an increase in the National In-
stitutes of Health Stroke Scale score of #3; and 2)
major stroke deﬁned as a new neurological deﬁcit
that persists for >30 days and increase in the
National Institutes of Health Stroke Scale score
of $4 (8).
Patients were considered at high surgical risk
if presenting with at least $1 high-risk criteria in
either medical comorbidities (80 years of age or older,
Canadian Cardiovascular Society angina class III or IV
or unstable angina, congestive heart failure class
III or IV, left ventricular ejection fraction <30%,
left main and/or 2-vessel coronary disease, urgent
[<30 days] heart surgery, recent myocardial infarc-
tion [<30 days], severe chronic lung disease, severe
renal disease) or anatomic criteria (high cervical
lesion, lesion below the clavicle, previous radicalneck surgery or radiation, carotid endarterectomy
restenosis, contralateral carotid occlusion, tracheos-
tomy, contralateral laryngeal nerve palsy) (1).
FOLLOW-UP. All patients received a follow-up clin-
ical assessment at 1 month. Clinical examination
assessed overall general conditions, neurological
signs and symptoms, medications, hospitalizations,
or any type of complication that occurred after the
procedure.
STATISTICAL ANALYSIS. Statistical analyses were
performed using SPSS version 16.0 (IBM, Chicago,
Illinois). Variables were expressed as absolute
numbers and percentages or mean  SD. Compari-
sons were made with the t test for unpaired samples
or the chi-square test as appropriate. To identify the
occlusion pressure (OP), occlusion time, and arterial
pressure delta threshold levels that provided the
best cutoff for OI prediction, we chose the values in
which the sum of the speciﬁcity and sensitivity was
the highest. This value was obtained by receiver-
operating characteristic curve analysis. The C-statis-
tic was used to assess the ability to classify risk.
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1240A multivariate logistic regression analysis was
performed to identify predictors of OI. The ﬁrst
model was built using the occurrence of OI as a
logistic binary variable and all the following vari-
ables as the predictors: $80 years of age or older;
male sex; smoking history; hypertension; diabetes;
hypercholesterolemia; chronic obstructive pulmo-
nary disease; coronary artery disease; symptomatic
status; the presence of string sign; the presence
of ICA stenosis >90%; the presence of ipsilateral
ECA stenosis; the presence of contralateral critical
ICA stenosis (75% to 99%) and occlusion; and OP
#40 mm Hg. A second model was then built using
OP #40 mm Hg as logistic binary variable and all the
following variables as the predictors: $80 years of
age or older; male sex; smoking history; hyper-
tension; diabetes; hypercholesterolemia; chronic
obstructive pulmonary disease; coronary artery dis-
ease; symptomatic status; the presence of the string
sign; the presence of ICA stenosis >90%; the presence
of ipsilateral ECA stenosis; the presence ofCharacteristics of the Patients According to the Occurrence
ion Intolerance
Intolerance
(n ¼ 184)
Tolerance
(n ¼ 421) p Value
71.5  7.6 70.6  8.2 0.192
yrs 26 (14.1) 62 (14.7) 0.848
124 (67.4) 297 (70.5) 0.438
ical risk 92 (50.0) 197 (46.8) 0.468
rs
126 (68.5) 311 (73.9) 0.173
nsion 175 (95.1) 371 (88.1) 0.008
olesterolemia 154 (83.7) 328 (77.9) 0.104
s mellitus 69 (37.5) 135 (32.1) 0.193
ty
111 (60.3) 210 (49.9) 0.018
matic CVD 34 (18.5) 77 (18.3) 0.956
19 (10.3) 43 (10.2) 0.967
ns
elet agents 184 (100) 421 (100)
ckers 91 (49.5) 181 (43.0) 0.141
ibitors 142 (77.2) 306 (72.7) 0.246
129 (70.1) 299 (71.0) 0.820
atures
osis $90% 43 (23.4) 141 (33.5) 0.013
al ECA stenosis >75% 4 (2.2) 18 (4.3) 0.204
teral ICA stenosis 75%–100% 39 (21.2) 52 (12.4) 0.005
teral ICA stenosis 75%–99% 20 (10.9) 35 (8.3) 0.314
teral occlusion 19 (10.3) 17 (4.0) 0.003
features
n pressure, mm Hg 42.3  12.7 61.9  15.4 <0.001
n time, s 288.7  107.7 291.7  127.0 0.782
pressure delta, mm Hg 31.2  28.7 25.9  21.9 0.015
(%) or mean  SD.
ions as in Table 1.contralateral critical ICA stenosis (75% to 99%); and
occlusion.
All statistical tests were 2-sided. For all tests, a
p value <0.05 was considered statistically signiﬁcant.
RESULTS
Table 1 shows the baseline characteristics of the
study population. The patient population enrolled in
this study exhibited a robust prevalence of cardio-
vascular risk factors. OI was observed in 181 patients
(29.9%); nevertheless, in all cases, CAS could be
concluded under cerebral protection. In most of these
cases, symptoms started after stent post-dilation,
during blood aspiration, and the procedure could be
concluded under proximal protection. Only 6 patients
(1.0%) showed immediate intolerance to balloon
occlusion. In these patients, we decided to deﬂate the
proximal balloon and use the Mo.Ma system as a
guiding catheter. Brieﬂy, the Mo.Ma was left in place
with only the distal balloon inﬂated, and a ﬁlter was
advanced in the ICA through the Mo.Ma working
channel. Once the ﬁlter device was correctly placed
distally to the lesion, stenting was completed under
distal protection.
Device and technical success was achieved in
all the patients. Protection success was achieved in
all but those 6 patients (98.9%) who experienced
immediate intolerance.
No patients died during the hospital stay, but
3 patients had a minor stroke and 2 patients had a
major nonfatal stroke. The cumulative in-hospital
incidence of death and stroke was 0.8%; conse-
quently, procedural success was achieved in 99.2%
of the cases. During the 30-day follow-up, no addi-
tional MACE occurred. Stroke incidence was not
signiﬁcantly different between patients in whom OI
developed (1.6%) and those in whom it did not
develop (0.5%; p ¼ 0.149). All patients received a
complete clinical assessment at 30 days.
Table 2 reports clinical and procedural charac-
teristics of the study population according to the
occurrence of OI. Notably, patients with OI were more
likely to be affected by hypertension and showed a
lower prevalence of subocclusive ICA stenosis
(Table 2). Not surprisingly, the presence of signiﬁcant
pathology of the contralateral ICA was associated
with higher rate of intolerance occurrence (Table 2).
No differences between the 2 groups were observed
with respect to other cardiovascular risk factors,
age, and the presence of comorbidities (Table 2).
Regarding procedural characteristics, patients in
whom OI developed had a signiﬁcantly lower OP and
post-procedural blood pressure decrease (Table 2).
TABLE 3 Characteristics of the Patients in Whom Immediate
Occlusion Intolerance Developed Versus Those in Whom Occlusion
Intolerance Developed Later During the Procedure
Immediate
(n ¼ 6)
Late
(n ¼ 178) p Value
Age, yrs 79.5  8.6 71.2  7.6 0.010
Age $80 yrs 3 (50.0) 23 (12.9) 0.010
Males 4 (66.7) 120 (67.4) 0.969
High surgical risk 3 (50.0) 89 (50.0) 1.000
Risk factors
Smoking 5 (83.3) 121 (68.0) 0.426
Hypertension 5 (83.3) 170 (95.5) 0.174
Hypercholesterolemia 3 (50.0) 151 (84.8) 0.023
Diabetes mellitus 3 (50.0) 66 (37.1) 0.520
Comorbidity
CAD 5 (83.3) 106 (59.6) 0.242
Symptomatic CVD 2 (33.3) 32 (18.0) 0.340
COPD 1 (16.7) 18 (10.1) 0.604
Medications
Antiplatelet agents 6 (100) 178 (100) 1.000
Beta-blockers 2 (33.3) 89 (50.0) 0.422
RAS inhibitors 3 (50.0) 139 (78.1) 0.107
Statins 1 (16.7) 128 (71.9) 0.004
Anatomic features
ICA stenosis $90% 1 (16.7) 42 (23.6) 0.693
Ipsilateral ECA stenosis
>75%
0 4 (2.2) 0.710
Contralateral ICA
stenosis 75%–100%
3 (50.0) 36 (20.2) 0.079
Contralateral ICA
stenosis 75%–99%
2 (33.3) 18 (10.1) 0.072
Contralateral occlusion 1 (16.7) 18 (10.1) 0.604
Procedure features
Occlusion pressure,
mm Hg
22.0  4.9 43.0  12.4 <0.001
Occlusion time, s 155.8  116.7 293.2  104.8 0.002
Arterial pressure delta,
mm Hg
10.0  10.9 31.9  28.8 0.066
Values are mean  SD or n (%).
Abbreviations as in Table 1.
FIGURE 1 Occlusion Pressure Receiver-Operating
Characteristic Curve
Receiver-operating characteristic curve showing sensitivity and
speciﬁcity of occlusion pressure in predicting occlusion intoler-
ance. AUC ¼ area under the curve; CI ¼ conﬁdence interval.
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1241Table 3 shows clinical and procedural characteris-
tics of patients in whom OI developed immediately
versus those in whom OI developed later during
the procedure. Interestingly, patients in whom OI
developed immediately were older those in whom
it developed later during the procedure. Of note,
OP and, obviously, occlusion time were signiﬁcantly
lower in immediate OI group.
PREDICTORS OF OI. Figure 1 displays the receiver-
operating characteristic curve for OP in relation to
the occurrence of OI. The OP cutoff value that pro-
vided the maximal sum of the speciﬁcity and sensi-
tivity in predicting the intolerance was #40 mm Hg.
The C-statistic (area under the curve) for OP was
0.85 (95% conﬁdence interval [CI]: 0.82 to 0.88, p <
0.0001). In contrast, the C-statistics for occlusiontime and arterial pressure delta were low and not
signiﬁcant (0.54, 95% CI: 0.49 to 0.57, p ¼ 0.157 and
0.54, 95% CI: 0.49 to 0.57, p ¼ 0.179, respectively).
The multivariate logistic regression analysis
showing the predictors of OI is shown in Figure 2.
The most powerful independent predictor was an
OP #40 mm Hg (odds ratio [OR]: 33.2, 95% conﬁdence
interval: 19.1 to 57.7). Also, hypertensive status con-
ferred a signiﬁcantly higher risk of the development
of OI (OR: 3.9, 95% CI: 1.5 to 10.3).
Figure 3 shows the clinical predictors of an
OP #40 mm Hg. The clinical predictors of OP were
the presence of contralateral ICA occlusion (OR: 3.1,
95% CI: 1.5 to 6.2) and, to a lesser extent, the presence
of hypercholesterolemia (OR: 1.8, 95% CI: 1.1 to 3.1).
Figures 4 and 5 show the inﬂuence of arterial
pressure delta and occlusion time on patients with
and without an OP #40 mm Hg. Of note, whereas in
patients with an OP #40 mm Hg, neither arterial
pressure delta nor occlusion time interferes with
intolerance occurrence, higher arterial pressure delta
($50 mm Hg) and occlusion time ($300 s) in those
with an OP >40 mm Hg increase the chances of
having OI.
DISCUSSION
Our study demonstrates the following. 1) The occur-
rence of OI is a frequent complication of proximal
protected CAS, occurring in as many as one-third of
FIGURE 2 Predictors of Occlusion Intolerance
Multivariate logistic regression analysis showing predictors of occlusion intolerance. x-axis:
1 ¼ age $80 years; 2 ¼ male sex; 3 ¼ smoking; 4 ¼ hypertension; 5 ¼ diabetes mellitus;
6 ¼ hypercholesterolemia; 7 ¼ chronic obstructive pulmonary disease; 8 ¼ coronary artery
disease; 9 ¼ symptomatic stenosis; 10 ¼ string sign; 11 ¼ contralateral stenosis (75% to
99%); 12 ¼ contralateral occlusion; 13 ¼ stenosis >90%; 14 ¼ external carotid artery
stenosis; 15 ¼ occlusion pressure #40 mm Hg. y-axis: odds ratio. Black circles ¼ p ¼ NS;
red circles ¼ p < 0.05.
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1242the patients and is not associated with an increased
risk of post-procedural MACE. 2) An OP #40 mm Hg
is the most powerful independent predictor of OI. 3)
An OP #40 mm Hg occurs more frequently in those
patients with concomitant contralateral ICA occlu-
sion. 4) In those patients with an OP >40 mm Hg, an
occlusion time >300 s or a post-procedural arterial
systolic blood pressure decrease of $50 mm Hg
increases the chances of OI.
It is accepted that EPDs lower the stroke risk
with CAS. In theory, a proximal EPD may afford
better neuroprotection for 2 important reasons.
First, a proximal EPD affords neuroprotection
throughout all phases of the procedure, includingrs of Occlusion Pressure #40 mm Hg
regression analysis showing predictors of OP # 40 mm Hg. x-axis: 1 ¼
male sex; 3 ¼ smoking; 4 ¼ hypertension; 5 ¼ diabetes mellitus; 6 ¼
a; 7 ¼ chronic obstructive pulmonary disease; 8 ¼ coronary artery
matic stenosis; 10 ¼ string sign; 11 ¼ contralateral stenosis (75% to
teral occlusion; 13 ¼ stenosis >90%; 14 ¼ external carotid
occlusion pressure #40 mm Hg. Y axis: odds ratio. Black circles ¼ p ¼
0.05.initial lesion crossing, whereas distal EPDs must
cross the lesion before neuroprotection can be
afforded. Proximal EPDs are able to capture partic-
ulate debris with high efﬁciency (2), and a direct
in vitro comparative study between proximal and
distal EPDs demonstrated better capture efﬁciency
of large particles for proximal EPDs (2). Clinical
studies using transcranial Doppler and/or diffusion-
weighted magnetic resonance imaging have sug-
gested that CAS-related microembolizations are
effectively reduced with the use of EPDs (5,9,10). A
recent meta-analysis demonstrated that the use of
proximal EPDs for neuroprotection in patients un-
dergoing CAS is associated with a minimal inci-
dence of total stroke (1.71%) and composite MACE
(2.25%) at 30 days (11).
Proximal occlusion devices stop or reverse ﬂow by
occluding the carotid artery, much in the same way
that a carotid endarterectomy accomplishes neuro-
protection. An OP #40 mm Hg after occlusion of
the CCA has been suggested to be a predictor of OI
(12,13) during proximal protected CAS, and our study
provides the deﬁnitive proof of this hypothesis.
Measuring blood pressure (stump pressure) in the
distal ICA during occlusion of the ICA is reported
to be a reliable safety index to predict ischemia
after permanent occlusion of the ICA (carotid sacri-
ﬁce) performed for the management of complex
cerebral aneurysms (14). Of note, the OP threshold of
40 mm Hg that we found associated with the devel-
opment of OI corresponds to the literature regarding
balloon test occlusion for carotid sacriﬁce used by
cerebral angiographers (14). Even if other studies
demonstrated in a different clinical setting that such
low pressure is associated with the development of
neurological symptoms, this is the ﬁrst study to
conﬁrm this ﬁnding in the setting of proximal pro-
tected CAS. Careful monitoring of the distal OP on
occlusion is therefore advised when proximal EPDs
are used.
Moreover, our study demonstrates that those
patients presenting a concomitant contralateral
ICA occlusion are at increased risk of having an
OP #40 mm Hg. With endarterectomy, a shunt is
used to provide antegrade perfusion to reduce the
risk of cerebral ischemia when a contralateral occlu-
sion is present, as this condition represents an
established high-risk feature and this is due to
compromise of the patient’s primary collateral
pathway. Similarly, in our study, the most powerful
clinical predictor of developing OI was contralateral
carotid occlusion because in patients with this con-
dition, the most important collateral pathway is
lacking. During CAS, no shunt is possible, so the
FIGURE 4 Occurrence of Occlusion Intolerance According to Occlusion
Pressure and Systolic Arterial Pressure Drop
Bar graph showing the rate of occurrence of occlusion intolerance according to occlusion
pressure and systolic arterial pressure decrease at procedure end.
FIGURE 5 Occurrence of Occlusion Intolerance According to Occlusion
Pressure and Occlusion Time
Bar graph showing the rate of occurrence of occlusion intolerance according to occlusion
pressure and occlusion time
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1243presence of a contralateral occlusion could determine
a poor tolerance of the device. During a proximal
protected CAS, however, the duration of arterial
occlusion is limited (3), and there are often other
avenues for collateralization from the posterior
circulation, and the device can be well tolerated, even
in the presence of a contralateral occlusion. In a
recent meta-analysis (11) on the use of proximal EPDs
during CAS, a contralateral occlusion was present
in 4.65% of the study population, yet OI requiring
interruption of use or a change to an alternate pro-
tection method occurred in <1% of the patients.
Furthermore, the presence of a contralateral occlu-
sion did not predict a higher incidence of MACE.
In high-volume centers with substantial experience
with proximal neuroprotection, application of ﬂow
reversal embolic protection in patients with con-
tralateral ICA occlusion has been done without an
increase in adverse events.
Of note, in our study, the occurrence of OI was more
frequent in hypertensive patients, and arterial hyper-
tension remains signiﬁcantly associated with a higher
risk of the development of OI also on multivariate
analysis, maybe because hypertensive patients are
used to higher cerebral perfusion pressures. Patients
with hypertension likely harbor an incompetent circle
ofWillis on cerebral angiography, and in the absence of
large intracranial vascular collaterals, in these pa-
tients, pial collaterals and increased systemic hyper-
tension are relied on to maintain their cerebral
perfusion. In addition, pial collaterals are more likely
to fail with endovascular occlusion.
Another important ﬁnding is that the presence of a
tight stenosis of the target vessel was more frequent
in those patients who did not experience OI, probably
because the vascular bed fed by the treated artery
is already adapted to hypoperfusion, whereas in pa-
tients with reduced stenosis severity, the ipsilateral
hemisphere relies more on the target artery for per-
fusion, and their collaterals have not been clinically
challenged before the procedure. Thus, a compre-
hensive evaluation of intracranial angiography and
collateral pathways may be the best way to predict
the development of OI before commitment of the
patient to MO.MA device, but the ﬁndings of our
study may be of great interest and utility because
they suggest the clinical predictors of poor tolerance
to this device, which can be evaluated before the
procedure is performed.
Finally, our study suggests that the operator must
pay a lot of attention to any procedural details. If
the OP is #40 mm Hg, the chance of having OI is
relatively high, and it will mostly occur during the
phase of blood aspiration; therefore, the operatorshould be aware of this possibility to be ready to
manage the patient’s symptoms. On the other hand,
if the OP is >40 mm Hg, the operator, to avoid the
risk of OI, should complete the procedure within
300 s, and the systolic blood pressure should be
monitored to avoid a decrease of $50 mm Hg, which
can occur after stent deployment or post-dilation. In
this regard, it is important to note that, in our study,
the vast majority of patients experienced OI late
in the procedure after stent post-dilation. This may
be due to 2 important reasons: 1) as endovascular
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1244occlusion proceeds, there is a natural fatiguing of
collateral patterns over time and 2) stent post-dilation
often induces systemic hypotension due to a vagal
response induced by carotid sinus manipulation, even
if in almost all cases atropine was used to minimize
this effect.
STUDY LIMITATIONS. This is a single center experi-
ence from a high volume institution with a robust
experience on the use of proximal protection for CAS.
The study’s ﬁnding should be conﬁrmed in a multi-
center registry before being adopted in the clinical
practice.CONCLUSIONS
Our study provides relevant information to identify
those patients who can experience OI during a prox-
imal protected CAS, an event that can be easily
managed if the operator is prepared to handle it.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Eugenio Stabile, Division of Cardiology, Department
of Advanced Biomedical Sciences, University of
Naples “Federico II”, Via Sergio Pansini 4, Naples NA
80131, Italy. E-mail: geko50@hotmail.com.RE F E RENCE S1. Brott TG, Halperin JL, Abbara S, et al. ASA/
ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/
SCAI/SIR/SNIS/SVM/SVS guideline on the man-
agement of patients with extracranial carotid
and vertebral artery disease: executive summary:
a report of the American College of Cardiology
Foundation/American Heart Association Task
Force on Practice Guidelines, and the American
Stroke Association, American Association of
Neuroscience Nurses, American Association of
Neurological Surgeons, American College of
Radiology, American Society of Neuroradiology,
Congress of Neurological Surgeons, Society of
Atherosclerosis Imaging and Prevention, Society
for Cardiovascular Angiography and Interventions,
Society of Interventional Radiology, Society of
NeuroInterventional Surgery, Society for Vascular
Medicine, and Society for Vascular Surgery. J Am
Coll Cardiol 2011;57:1002–44.
2. Stabile E, Biamino G, Sorropago G, Rubino P.
Proximal endovascular occlusion for carotid artery
stenting. J Cardiovasc Surg (Torino) 2013;54:41–5.
3. Stabile E, Salemme L, Sorropago G, et al.
Proximal endovascular occlusion for carotid
artery stenting: results from a prospective registry
of 1,300 patients. J Am Coll Cardiol 2010;55:
1661–7.
4. Ansel GM, Hopkins LN, Jaff MR, et al., In-
vestigators for the ARMOUR Pivotal Trial. Safety
and effectiveness of the INVATEC MO.MAproximal cerebral protection device during carotid
artery stenting: results from the ARMOUR pivotal
trial. Catheter Cardiovasc Interv 2010;76:1–8.
5. Bijuklic K, Wandler A, Hazizi F, Schofer J. The
PROFI study (Prevention of Cerebral Embolization
by Proximal Balloon Occlusion Compared to Filter
Protection During Carotid Artery Stenting): a
prospective randomized trial. J Am Coll Cardiol
2012;59:1383–9.
6. Stabile E, Sorropago G, Tesorio T, et al. Use
of endovascular occlusion as neuroprotection
during carotid stenting in the presence of a critical
ipsilateral stenosis of the external carotid artery.
EuroIntervention 2008;3:588–92.
7. Stabile E, Sorropago G, Tesorio T, et al. Heparin
versus bivalirudin for carotid artery stenting
using proximal endovascular occlusion for neuro-
protection: results from a prospective randomized
study. J Vasc Surg 2010;52:1505–10.
8. Brott T, Adams HP, Olinger CP, et al. Mea-
surements of acute cerebral infarction: a clinical
examination scale. Stroke 1989;20:864–70.
9. Schmidt A, Diederich KW, Scheinert S, et al.
Effect of two different neuroprotection systems
on microembolization during carotid artery
stenting. J Am Coll Cardiol 2004;44:1966–9.
10. Montorsi P, Caputi L, Galli S, et al. Micro-
embolization during carotid artery stenting inpatients with high-risk, lipid-rich plaque. A
randomized trial of proximal versus distal
cerebral protection. J Am Coll Cardiol 2011;58:
1656–63.
11. Bersin RM, Stabile E, Ansel GM, et al. A meta-
analysis of proximal occlusion device outcomes in
carotid artery stenting. Catheter Cardiovasc Interv
2012;80:1072–8.
12. Reimers B, Sievert H, Schuler GC, et al.
Proximal endovascular ﬂow blockage for
cerebral protection during carotid artery
stenting: results from a prospective multi-
center registry. J Endovasc Ther 2005;12:
156–65.
13. Diederich KW, Scheinert D, Schmidt A, et al.
First clinical experiences with an endovascular
occlusion system for neuroprotection during
carotid stenting. Eur J Vasc Endovasc Surg 2004;
28:629–33.
14. Kurata A, Miyasaka Y, Tanaka C, Ohmomo T,
Yada K, Kan S. Stump pressure as a guide to the
safety of permanent occlusion of the internal
carotid artery. Acta Neurochir (Wien) 1996;138:
549–54.KEY WORDS carotid artery stenting,
endovascular occlusion, occlusion
intolerance
